With over 30 years of experience in the UK (licensed in December 1990),1 Dysport® is well tolerated in adults with cervical dystonia.2,3
Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex)
Tolerability information
Adverse events reported for cervical dystonia in the Dysport® SmPC2
| System organ class | Frequency* | Adverse drug reaction |
|---|---|---|
| Nervous system disorders | Common | Headache, dizziness, facial paresis |
| Eye disorders | Common Uncommon |
Vision blurred, visual acuity reduced Diplopia, ptosis |
| Respiratory, thoracic and mediastinal disorders | Common Rare |
Dysphonia, dyspnoea Aspiration |
| Gastrointestinal disorders | Very common Uncommon |
Dysphagia†, dry mouth Nausea |
| Musculoskeletal and connective tissue disorders | Very common Common Uncommon |
Muscle weakness Neck pain, musculoskeletal pain, myalgia, pain in extremity, musculoskeletal stiffness Muscle atrophy, jaw disorder |
*The frequency of AEs reported in placebo-controlled trials after a single administration is defined as: very common ≥1/10; common ≥1/100 to <1/10; uncommon ≥1/1000 to <1/100; rare ≥1/10 000 to <1/1000.2
†Dysphagia appeared to be dose related and occurred most frequently following injection into the sternomastoid muscle. A soft diet may be required until symptoms resolve. These side effects may be expected to resolve within 2–4 weeks.2
References:
- IPSEN Data on File: DYS-UK-003254.
- Dysport® Summary of Product Characteristics.
- Truong D, et al. Parkinsonism Relat Disord. 2010;16:316–323.
Abbreviations:
AE, adverse event; SmPC, Summary of Product Characteristics.
For further information, please refer to the Prescribing Information or the Summary of Product Characteristics.